Pain and Stress Management for Fibromyalgia
Emotional Exposure and Cognitive Behavioral Therapies for Fibromyalgia
1 other identifier
interventional
230
1 country
3
Brief Summary
This interventional, randomized controlled study seeks to test the effects of an innovative emotional exposure and processing treatment that targets stress resolution, by comparing it with cognitive-behavioral therapy and a Fibromyalgia education comparison condition. The investigators also will test proposed mediators of the intervention, including improved autonomic regulation, and explore which subgroups of patients benefit the most from each approach.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started May 2011
Typical duration for phase_2
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 2, 2010
CompletedFirst Posted
Study publicly available on registry
February 1, 2011
CompletedStudy Start
First participant enrolled
May 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2015
CompletedMarch 17, 2016
March 1, 2016
4.2 years
November 2, 2010
March 15, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Brief Pain Inventory
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Secondary Outcomes (23)
SF-12
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
PROMIS Fatigue short form
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Pittsburgh Sleep Quality Index
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Center for Epidemiological Studies - Depression Scale
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Generalized Anxiety Disorder - 7
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
- +18 more secondary outcomes
Study Arms (3)
Stress and Emotions
EXPERIMENTALSeeks to reduce stress and physical symptoms by helping individual become aware of their emotions, express them, and resolve emotional difficulties. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
Thoughts and Behaviors
ACTIVE COMPARATORSeeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms of fibromyalgia. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
Brain and Body
ACTIVE COMPARATORSeeks to help individuals improve health by educating about fibromyalgia so that one can better understand and more effectively communicate about their health. It will explain the latest scientific information about fibromyalgia, including its causes, the role of the nervous system and body, various medical and alternative treatments, and how to understand research findings.
Interventions
Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
Focus on the empowering patients by providing the latest scientific information about fibromyalgia, including causes, the role of the nervous system, and various treatments.
Eligibility Criteria
You may qualify if:
- Meet Fibromyalgia (FM) criteria of the American College of Rheumatology (ACR)either:
- ACR criteria including tender points
- ACR modified clinical criteria that does not include tender points
You may not qualify if:
- Co-morbid autoimmune disorders, including rheumatoid arthritis and systemic lupus
- Other serious medical conditions that can impair health status independent of FM
- Current psychotic disorders (schizophrenia, bipolar disorder, etc.),dissociative identity (multiple personality) disorder, active suicide risk
- Alcohol/drug dependence in past 2 years
- Cognitive impairment or dementia
- Currently have pending (or recently received - within 2 years) FM pain related disability or workman's compensation
- Unable to fluently read or converse in English
- Planning to move from the area in the next 14 months
- Judgment of principle investigator as not appropriate for this trial or all intervention arms
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Wayne State Universitylead
- University of Michigancollaborator
- St. John Providence Hospitalcollaborator
Study Sites (3)
University of Michigan Medical Center
Ann Arbor, Michigan, 48106, United States
Wayne State University
Detroit, Michigan, 48202, United States
St. John Providence Hospital
Southfield, Michigan, 48075, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mark A Lumley, Ph.D.
Wayne State University
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
November 2, 2010
First Posted
February 1, 2011
Study Start
May 1, 2011
Primary Completion
July 1, 2015
Study Completion
July 1, 2015
Last Updated
March 17, 2016
Record last verified: 2016-03